

IN THE CLAIMS:

Claims 1-6 have been cancelled.

²
7. (Previously presented) A method for the preparation of the entire HCMV pp28 which comprises expressing the expression vector which codes for said entire HCMV pp28 as claimed in claim ¹73.

Claims 8-36 have been cancelled.

³³
37. (Previously presented) An isolated 0.5 kB KpnI/SmaI fragment encoding an antigenic portion of HCMV pp28 that elicits antibodies that immunologically bind to pp28.

Claim 38 has been cancelled.

³⁴
39. (Previously presented) An isolated 1.0 kB SmaI/SmaI fragment encoding an antigenic portion of HCMV pp28 that elicits antibodies that immunologically bind to pp28.

Claim 40 has been cancelled.

⁴
41. (Previously presented) The prokaryotic expression vector of claim ³74, wherein said expression vector is bacteriophage vector.

⁵
42. (Previously presented) The prokaryotic expression vector of claim ³74, wherein said prokaryotic expression vector is a lambda phage vector.

⁶
43. (Previously presented) The prokaryotic expression vector of claim ³74, wherein said prokaryotic expression vector encodes a fusion protein.

Claim 44 has been cancelled.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

⁷45. (Previously presented) The prokaryotic expression vector of claim ³74, wherein said prokaryotic expression vector comprises a 1.0 kB SmaI/SmaI fragment of HCMV.

⁸46. (Previously presented) The prokaryotic expression vector of claim ³74, wherein said prokaryotic expression vector comprises a 0.5 kB KpnI/SmaI fragment of HCMV.

⁹47. (Previously presented) The prokaryotic expression vector of claim ³74, wherein said prokaryotic expression vector comprises a 0.5 kB SmaI/KpnI fragment of HCMV.

¹⁷48. (Previously presented) The prokaryotic cell of claim ¹⁶76, wherein said prokaryotic cell is a bacterium.

¹⁸49. (Previously presented) The prokaryotic cell of claim ¹⁶76, wherein said prokaryotic cell is *E. coli*.

¹⁹50. (Previously presented) The prokaryotic cell of claim ¹⁶76, wherein said DNA molecule comprises a 1.0 kB SmaI/SmaI fragment of HCMV.

²⁰51. (Previously presented) The prokaryotic cell of claim ¹⁶76, wherein said DNA molecule comprises a 0.5 kB KpnI/SmaI fragment of HCMV.

²¹52. (Previously presented) The prokaryotic cell of claim ¹⁶76, wherein said DNA molecule comprises a 0.5 kB SmaI/KpnI fragment of HCMV.

Claims 53-57 have been cancelled.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

²⁶
~~58.~~ (Previously presented) The eukaryotic cell of claim ²⁵~~83~~, wherein said DNA molecule comprises a 1.0 k~~8~~b SmaI/SmaI fragment of HCMV.

²⁷
~~59.~~ (Previously presented) The eukaryotic cell of claim ²⁵~~83~~, wherein said DNA molecule comprises a 0.5 k~~8~~b KpnI/SmaI fragment of HCMV.

²⁸
~~60.~~ (Previously presented) The eukaryotic cell of claim ²⁵~~83~~, wherein said DNA molecule comprises a 0.5 k~~8~~b SmaI/KpnI fragment of HCMV.

Claim 61 has been cancelled.

³⁵
~~62.~~ (Previously presented) An isolated 0.5 k~~8~~b KpnI/SmaI fragment encoding an antigenic portion of HCMV pp28 strain Ad 169 that elicits antibodies that immunologically bind to pp28.

³⁶
~~63.~~ (Previously presented) An isolated 1.0 k~~8~~b SmaI/SmaI fragment encoding an antigenic portion of HCMV pp28 strain Ad 169 that elicits antibodies that immunologically bind to pp28.

¹⁶
~~64.~~ (Previously presented) The prokaryotic expression vector of claim ³~~74~~, wherein said prokaryotic expression vector comprises a 1.0 k~~8~~b SmaI/SmaI fragment of HCMV strain Ad 169.

¹¹
~~65.~~ (Previously presented) The prokaryotic expression vector of claim ³~~74~~, wherein said prokaryotic expression vector comprises a 0.5 k~~8~~b KpnI/SmaI fragment of HCMV strain Ad 169.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

¹²
66. (Previously presented) The prokaryotic expression vector of claim ³74, wherein said prokaryotic expression vector comprises a 0.5 kB SmaI/KpnI fragment of HCMV strain Ad 169.

²²
67. (Previously presented) The prokaryotic cell of claim ¹⁶76, wherein said DNA molecule comprises a 1.0 kB SmaI/SmaI fragment of HCMV strain Ad 169.

²³
68. (Previously presented) The prokaryotic cell of claim ¹⁶76, wherein said DNA molecule comprises a 0.5 kB KpnI/SmaI fragment of HCMV strain Ad 169.

²⁴
69. (Previously presented) The prokaryotic cell of claim ¹⁶76, wherein said DNA molecule comprises a 0.5 kB SmaI/KpnI fragment of HCMV strain Ad 169.

²⁹
70. (Previously presented) The eukaryotic cell of claim ²⁵83, wherein said DNA molecule comprises a 1.0 kB SmaI/SmaI fragment of HCMV strain Ad 169.

³⁰
71. (Previously presented) The eukaryotic cell of claim ²⁵83, wherein said DNA molecule comprises a 0.5 kB KpnI/SmaI fragment of HCMV strain Ad 169.

³¹
72. (Previously presented) The eukaryotic cell of claim ²⁵83, wherein said DNA molecule comprises a 0.5 kB SmaI/KpnI fragment of HCMV strain Ad 169.

¹
73. (Previously presented) A prokaryotic expression vector encoding the entire HCMV pp28 that elicits antibodies that immunologically bind to pp28, wherein said vector expresses said entire HCMV pp28 in prokaryotic cells.

³
74. (Previously presented) A prokaryotic expression vector encoding an antigenic portion of HCMV pp28 that elicits antibodies that immunologically bind to

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

pp28, wherein said vector expresses said antigenic portion of HCMV pp28 in prokaryotic cells.

¹⁴
~~75.~~ (Previously presented) A prokaryotic cell which is transformed with a recombinant DNA molecule encoding the entire HCMV pp28 that elicits antibodies that immunologically bind to pp28, wherein said cell expresses said entire HCMV pp28.

¹⁶
~~76.~~ (Previously presented) A prokaryotic cell which is transformed with a recombinant DNA molecule encoding an antigenic portion of HCMV pp28 that elicits antibodies that immunologically bind to pp28, wherein said cell expresses said antigenic portion of HCMV pp28.

Claims 77-79 have been cancelled

¹⁵
~~80.~~ (Previously presented) The prokaryotic cell of claim ¹⁴~~75~~, wherein said prokaryotic cell is a bacterium.

Claim 81 has been cancelled

³²
~~82.~~ (Previously presented) A eukaryotic cell which is transformed with a recombinant DNA molecule encoding the entire HCMV pp28 that elicits antibodies that immunologically bind to pp28, wherein said cell expresses said entire HCMV pp28 in said cell.

²⁸
~~83.~~ (Previously presented) A eukaryotic cell which is transformed with a recombinant DNA molecule encoding an antigenic portion of HCMV pp28 that elicits antibodies that immunologically bind to pp28, wherein said cell expresses said antigenic portion of HCMV pp28 in said cell.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Claims 84-86 have been cancelled.

¹³
~~87~~. (Previously presented) A method for the preparation of an antigenic portion of HCMV pp28 which comprises expressing the expression vector which codes for said antigenic portion of HCMV pp28 as claimed in claim ³~~74~~.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com